WALTHAM, Mass., Nov. 6, 2014 /PRNewswire/ -- NKT Therapeutics, a clinical stage biotechnology company, today announced that its scientists and collaborators will present preclinical and clinical data on the company’s program for the treatment of sickle cell disease at the American Society of Hematology Annual Meeting being held in San Francisco from December 6th-9th 2014. Amongst the data to be presented will be the most recent results from NKTT’s Phase 1b clinical trial of NKTT120 in patients with sickle cell disease.
Presentations from NKTT scientists and collaborators include:
- A poster entitled “NKTT120 Reduces iNKT Cells without Dose Limiting Toxicity in Stable Adult Sickle Cell Patients in a Phase 1 Trial” to be presented from 6-8 PM on December 7th
- A poster entitled “Adult Patients with Stable Sickle Cell Disease Prior to Treatment with the iNKT Cell Depleting Antibody NKTT120 Have Consistent and Elevated Numbers of Activated (CD69+) iNKT Cells Relative to Healthy Adult Volunteers” to be presented on December 8th from 6-8 PM.
- A poster entitled “Antibody Mediated Depletion of iNKT Cells Protects Against Hypoxia-Induced Pulmonary Injury in a Murine Model of Sickle Cell Disease” to be presented on December 7th from 6-8 PM.
About NKT Therapeutics
NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company’s mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat sickle cell disease, autoimmune and inflammatory diseases, and cancer. For more information on the company, please visit http://www.nktrx.com.
Logo - http://photos.prnewswire.com/prnh/20121203/MM23274LOGO
SOURCE NKT Therapeutics
Help employers find you! Check out all the jobs and post your resume.
